Invesco
ZNTL icon

Invesco’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Invesco’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$294K Sell
125,767
-62,815
-33% -$162K ﹤0.01% 3344
2025
Q4 		$255K Buy
188,582
+14,961
+9% +$21.8K ﹤0.01% 3448
2025
Q3 		$262K Buy
173,621
+17,907
+11% +$26.8K ﹤0.01% 3471
2025
Q2 		$181K Buy
155,714
+6,230
+4% +$8.22K ﹤0.01% 3537
2025
Q1 		$238K Buy
149,484
+98,612
+194% +$213K ﹤0.01% 3441
2024
Q4 		$154K Sell
50,872
-590
-1% -$1.93K ﹤0.01% 3561
2024
Q3 		$189K Sell
51,462
-2,347
-4% -$8.53K ﹤0.01% 3529
2024
Q2 		$220K Sell
53,809
-557
-1% -$6.22K ﹤0.01% 3595
2024
Q1 		$857K Buy
54,366
+29,416
+118% +$405K ﹤0.01% 3070
2023
Q4 		$378K Sell
24,950
-111,611
-82% -$1.63M ﹤0.01% 3356
2023
Q3 		$2.74M Buy
136,561
+6,281
+5% +$159K ﹤0.01% 2481
2023
Q2 		$3.68M Buy
130,280
+104,647
+408% +$2.51M ﹤0.01% 2394
2023
Q1 		$441K Buy
25,633
+575
+2% +$11.6K ﹤0.01% 3330
2022
Q4 		$505K Sell
25,058
-1,958
-7% -$42.1K ﹤0.01% 3260
2022
Q3 		$586K Buy
27,016
+3,391
+14% +$92.7K ﹤0.01% 3169
2022
Q2 		$664K Sell
23,625
-73,830
-76% -$1.96M ﹤0.01% 3192
2022
Q1 		$4.5M Sell
97,455
-121,660
-56% -$6.56M ﹤0.01% 2432
2021
Q4 		$18.4M Buy
219,115
+88,303
+68% +$6.83M ﹤0.01% 1620
2021
Q3 		$8.72M Sell
130,812
-14,437
-10% -$833K ﹤0.01% 2079
2021
Q2 		$7.73M Sell
145,249
-87,758
-38% -$4.7M ﹤0.01% 2214
2021
Q1 		$10.1M Sell
233,007
-43,062
-16% -$1.85M ﹤0.01% 1945
2020
Q4 		$14.3M Buy
276,069
+2,960
+1% +$134K ﹤0.01% 1616
2020
Q3 		$8.93M Sell
273,109
-4,284
-2% -$150K ﹤0.01% 1708
2020
Q2 		$13.3M Buy
+277,393
New +$10.6M ﹤0.01% 1478

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Invesco's ZNTL Position: Q1 2026 in Review

Invesco reduced its Zentalis Pharmaceuticals (ZNTL) stake by 33% in Q1 2026, selling an estimated $162K and leaving 125,767 shares worth $294K. The position accounts for ﹤0.01% of the portfolio, ranked #3344.

Invesco first reported a position in ZNTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $18.4M in Q4 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Invesco held 125,767 shares of Zentalis Pharmaceuticals worth $294K as of Q1 2026.
  • Invesco sold 62,815 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $162K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3344 holding.
  • Invesco first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Invesco's Zentalis Pharmaceuticals position peaked at $18.4M in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.